Kiora Pharmaceuticals Appoints Keith J. Lane as Executive Vice President of Global Clinical Development and Regulatory Affairs
Kiora adds a seasoned ophthalmology trial and regulatory leader to guide its global pipeline, including programs such as KIO-301.
Rhea-AI Summary
Kiora Pharmaceuticals (KPRX) appointed Keith J. Lane, MBA, as Executive Vice President of Global Clinical Development and Regulatory Affairs, effective with the announcement on September 8, 2026.
Lane brings over 20 years of experience in ophthalmic drug development, clinical operations and regulatory strategy across Phase 1 through Phase 4 clinical trials. The company said he will oversee U.S. and global clinical development and registration studies for Kiora’s current pipeline, including support for KIO-301 in retinitis pigmentosa and other inherited retinal diseases, and help advance future pipeline assets. Lane joins from ophthalmology-focused contract research organization Ora, where he most recently served as Chief Scientific Officer and worked across small molecules, biologics, gene therapies and cell therapies in multiple retinal and optic nerve disorders and inflammatory eye conditions.
Positive
- None.
Negative
- None.
Key Figures
- Ophthalmology experience
- over 20 years
- Mr. Lane's ophthalmic drug development experience
- Ophthalmic trials overseen
- more than 60 trials
- During Mr. Lane's tenure at Ora
- Global Phase 3 studies
- 12 studies
- Global Phase 3 pivotal studies overseen
- New drug application submissions
- 3 submissions
- Supported by the Phase 3 studies
- Biologics license application submissions
- 1 submission
- Supported by the Phase 3 studies
Key Terms
retinitis pigmentosa medical
new drug application regulatory
biologics license application regulatory
gene therapies medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Clinical development executive brings over 20 years of ophthalmology experience supporting U.S. and global clinical trials to support the advancement of Kiora's pipeline and new asset opportunities
Encinitas, California--(Newsfile Corp. - September 8, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced the appointment of Keith J. Lane, MBA, as Executive Vice President of Clinical Development and Regulatory Affairs. Mr. Lane has over 20 years of experience in ophthalmic drug development, clinical development and operations and regulatory strategy across Phase 1 through Phase 4 clinical trials.
"Keith has substantial experience supporting U.S. and global clinical programs across retinal diseases, optic neuropathies and other ophthalmic indications," said Brian M. Strem, Ph.D., President and Chief Executive Officer of Kiora. "He brings the ability to connect clinical strategy with trial execution, to assess therapeutic activity, support regulatory approval, and generate evidence-driven data to drive physician adoption and payer coverage. Keith has built a vast network of ophthalmic KOLs who can potentially add further value to Kiora's pipeline. His responsibilities will encompass U.S. and global clinical development and registration studies for our current pipeline, supporting KIO-301 for retinitis pigmentosa and other inherited retinal diseases, as needed by our partners, and helping advance potential future pipeline assets."
Mr. Lane joins Kiora from Ora, Inc., an ophthalmology-focused clinical research organization, where he most recently served as the Chief Scientific Officer. During his tenure, he oversaw clinical operations and regulatory strategy for more than 60 ophthalmic trials, including 12 global Phase 3 pivotal studies that supported three new drug application submissions and one biologics license application submission. His experience spans small molecules, biologics, gene therapies and cell therapies across retinal disease, inherited retinal disease, glaucoma, optic neuropathies and inflammatory eye conditions.
"I was attracted to Kiora by its science, its team and its strategy of developing small molecules that target novel biological pathways," Mr. Lane said. "This approach could provide new ways to treat or prevent vision loss caused by progressive degenerative and acute, vision-threatening retinal diseases. Kiora's commitment to addressing rare and broader-market diseases with limited or no treatment options aligns closely with my personal motivation to help bring meaningful therapies to patients in need."
Mr. Lane earned an MBA in health sector management, with honors, from Boston University's Questrom School of Business and a Bachelor of Science from Bates College.
About Kiora Pharmaceuticals
Kiora Pharmaceuticals is a clinical-stage biotechnology company developing therapies for retinal disease. The Company targets critical pathways underlying retinal diseases using small molecules designed to slow, stop or restore vision loss. KIO-301 is being developed initially for retinitis pigmentosa, with potential expansion into choroideremia and Stargardt disease. KIO-104 is being developed for macular edema associated with retinal inflammation.
In addition to news releases and SEC filings, Kiora posts information on its website, www.kiorapharma.com, and social media accounts that could be relevant to investors. Investors are encouraged to follow Kiora on X and LinkedIn and subscribe to email alerts.
Contacts
Investors
Investors@kiorapharma.com
Media
Susan Sharpe
Linnden Communications
susan@linndencom.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/313082
FAQ
What specific responsibilities will Keith J. Lane have at Kiora Pharmaceuticals?
Keith J. Lane’s responsibilities will include overseeing U.S. and global clinical development and registration studies for Kiora’s current pipeline. This covers support for KIO-301 in retinitis pigmentosa and other inherited retinal diseases, as needed by Kiora’s partners, and helping to advance potential future pipeline assets. The company also highlights his role in connecting clinical strategy with trial execution, assessing therapeutic activity, supporting regulatory approval, and generating evidence-driven data to aid physician adoption and payer coverage.
What relevant experience does Keith J. Lane bring from his role at Ora?
At Ora, an ophthalmology-focused clinical research organization, Keith J. Lane most recently served as Chief Scientific Officer. During his tenure, he oversaw clinical operations and regulatory strategy for more than 60 ophthalmic trials, including 12 global Phase 3 pivotal studies that supported three new drug application submissions and one biologics license application submission. His work covered small molecules, biologics, gene therapies and cell therapies across retinal disease, inherited retinal disease, glaucoma, optic neuropathies and inflammatory eye conditions.
What reasons did Keith J. Lane give for joining Kiora Pharmaceuticals?
Keith J. Lane stated that he was attracted to Kiora by its science, its team and its strategy of developing small molecules that target novel biological pathways. He said this approach could offer new ways to treat or prevent vision loss in progressive degenerative and acute, vision-threatening retinal diseases. Lane added that Kiora’s focus on rare and broader-market diseases with limited or no treatment options aligns with his personal motivation to help bring meaningful therapies to patients in need.